1. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis 
Patricia M. Howse, BSc, Lyudmila N. Chibrikova, PhD, Laurie K. Twells, PhD, Brendan J. Barrett, MD, MSc, FRCPC, John-Michael Gamble, PhD 
American Journal of Kidney Diseases 
Volume 68, Issue 5, Pages (November 2016)
DOI: /j.ajkd
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
Study flow diagram. Abbreviation: KDOQI, Kidney Disease Outcomes Quality Initiative.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 The Authors Terms and Conditions

3. Figure 2 Risk-of-bias summary.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 The Authors Terms and Conditions

4. Figure 3
Forest plots for relative treatment effect of incretins versus placebo and active comparators for primary outcomes: (A) Change in glycated hemoglobin (HbA1c) level (percent) for incretin versus placebo, (B) change in HbA1c level for incretin versus active comparator, (C) hypoglycemia for incretin versus placebo, and (D) hypoglycemia for incretin versus active comparator. Weights are from random effects (RE) analysis. Abbreviations: CI, confidence interval; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 The Authors Terms and Conditions